Clinical trials: Mental Depression
Major Depressive Disorder
Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder
To evaluate the efficacy and safety of quetiapine fumarate sustained release (Seroquel SR) in the treatment of Major Depressive Disorder. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation.
- Trial name
- AMBER (NCT00351169)
- Testing
- Quetiapine SR, Escitalopram
- Where
- 42 sites in Canada, China and 7 more
- Volunteers
- 450 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)
A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression.
- Trial name
- NCT00048594
- Testing
- aprepitant
- Volunteers
- 800 people
- Sponsor
- Merck Sharp & Dohme LLC
Depression - Major Depressive Disorder
BIOMARKERS FOR DRUG SELECTION IN DEPRESSION
The study aims to assess whether providing Clinical Decision Support Software (CDSS) information improves the pharmacological response in patients with depression.
- Trial name
- 3BD-Test (NCT07269886)
- Where
- Argentina
- Volunteers
- 79 people
- Sponsor
- Neomente SAS
Depressive Disorder, Major, Major Depressive Disorder (MDD)
A Local Register Study For Major Depression Of Paroxetine Controlled Release
The study is to investigate the non-inferior efficacy of Paroxetine Controlled Release to Paroxetine Immediate Release, as well as the drug tolerability profile when treated on patients with Major Depression.
- Trial name
- NCT00368303
- Testing
- Paroxetine CR, Paroxetine IR
- Where
- 11 sites in China
- Volunteers
- 362 people
- Sponsor
- GlaxoSmithKline
Suicide, Mental Health Disorder
Optimizing a Just-in-time Adaptive Intervention for Suicide Safety Planning in Adolescents
Despite efforts to prevent suicide, US rates are climbing, and suicide is the second leading cause of death amongst youth. Digital tools, especially personal smartphones, are promising avenues to address these issues and can be…
- Conditions
- Suicide, Mental Health Disorder, Anhedonia
- Trial name
- NCT06665620
- Testing
- ViraBrite nudges
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Ksana Health
Depressive Disorder, Major
Study Of The Effects Of A New Antidepressant Therapy In Patients With Major Depressive Disorder (MDD)
The purpose of this study is to assess the efficacy, safety and tolerability of GW679769 patients with Major depressive Disorder (MDD).
- Trial name
- NCT00413023
- Testing
- GW679769
- Where
- 39 sites in Argentina, Belgium and 9 more
- Volunteers
- 348 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder (MDD)
A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Adult Participents With Major Depressive Disorder
This is a two-part (open-label followed by double-blind) study evaluating the safety, tolerability, pharmacokinetics, and efficacy of KH607 in 120 participants diagnosed with moderate or severe Major Depressive Disorder.
- Trial name
- NCT07101120
- Testing
- KH607 tablets
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Major Depressive Disorder
A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder
To evaluate the efficacy, safety, and tolerability of NBI-1070770 compared to placebo on improving symptoms of depression in participants with major depressive disorder (MDD).
- Trial name
- NCT06267846
- Testing
- NBI-1070770
- Where
- 13 sites in United States
- Volunteers
- 73 people
- Sponsor
- Neurocrine Biosciences
Major Depressive Disorder
Open-Label Treatment With Duloxetine Hydrochloride Once-Daily Dosing for Evaluation of Stabilization Dose in Patients With Major Depression
The purposes of this study are to determine: The safety of duloxetine and any side effects that might be associated with it. Whether duloxetine can help patients with major depression.
- Trial name
- NCT00042562
- Testing
- duloxetine
- Where
- 23 sites in United States
- Sponsor
- Eli Lilly and Company
Depression
Optimizing Clinical Screening and Management of Maternal Mental Health: Predicting Women at Risk for Perinatal Depression
The purpose of this study is to determine if medical, biological, psychological, and social risk factors can be used to develop algorithms that will predict perinatal depression (PND).
- Trial name
- NCT03144752
- Where
- United States
- Volunteers
- 298 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Stress, Depression
Cocooned Moms Study
The Cocooned Moms Study is a pre- and post-design study primarily aimed at reducing stress, depressive symptoms, and blood pressure among expectant Black women by providing them with free access to the InovCares mobile app.
- Conditions
- Stress, Depression, Pregnancy, Blood Pressure
- Trial name
- Cocooned Moms (NCT06968650)
- Testing
- Digital and Coordinated Maternial Care
- Where
- 2 sites in United States
- Volunteers
- 384 people
- Sponsor
- InovCares Connected Comprehensive Healthcare Corporation
Anxiety Disorders, Depression
Study Evaluating Venlafaxine Extended-Release in Depressed and Anxious Patients
To examine the efficacy and safety of venlafaxine XR in the treatment of physical and emotional symptoms in patients with an operationally-defined diagnosis of multisomatoform disorder (MSD).
- Trial name
- NCT00546923
- Testing
- Venlafaxine XR
- Volunteers
- 210 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder
Pharmacokinetics and Safety of Desvenlafaxine in Korean Healthy Subjects Following Single and Multiple Oral Doses of Desvenlafaxine Succinate Sustained Release Tablet
To evaluate the pharmacokinetics and safety of single dose and multiple doses of desvenlafaxine in Korean healthy subjects and compare to westerners.
- Trial name
- NCT01443208
- Testing
- desvenlafaxine
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Pfizer
Major Depressive Disorder
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
- Trial name
- NCT06911112
- Testing
- NBI-1065845
- Where
- 39 sites in United States, Bulgaria and 3 more
- Volunteers
- 200 people
- Sponsor
- Neurocrine Biosciences
Major Depressive Disorder
Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD)
The study will assess efficacy, safety and tolerability of 0.5 mg/day and 1 mg/day of sublingual (under the tongue) formulation of agomelatine in patients with Major Depressive Disorder.
- Trial name
- NCT01110902
- Testing
- Agomelatine (AGO178C)
- Where
- 45 sites in United States, Puerto Rico
- Volunteers
- 589 people
- Sponsor
- Novartis Pharmaceuticals
Covid19
Efficacy of Adaptogens in Patients With Long COVID-19
The aim of this clinical trial of a fixed combination of standardized extracts from Rhodiola rosea roots, Schisandra chinensis berry and Eleutherococcus senticosus root (ADAPT-232) in COVID-19 patients is to demonstrate possible…
- Trial name
- NCT04795557
- Testing
- ADAPT-232 oral solution
- Where
- Georgia
- Volunteers
- 100 people
- Sponsor
- Swedish Herbal Institute AB
Major Depressive Disorder
Safety Study of F2695 SR in Major Depressive Disorder
The purpose of this study is to evaluate the long- term safety of F2695-SR in the treatment of adults with major depressive disorder.
- Trial name
- LVM-MD-04 (NCT01034267)
- Testing
- F2695 SR
- Where
- 68 sites in United States
- Volunteers
- 828 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
AZD7268 Safety and Tolerability Study
The purpose of this study is to prove the principle that treatment with AZD7268 reduces depressive symptoms in patients with Major Depressive Disorder (MDD) compared with placebo.
- Trial name
- NCT01020799
- Testing
- AZD7268, Escitalopram
- Where
- 17 sites in United States
- Volunteers
- 247 people
- Sponsor
- AstraZeneca
Unipolar Depression
Validation of the Spanish Version of the Clinically Useful Depression Outcome Scale (CUDOS) Scale
The Clinically Useful Depression Outcome Scale (CUDOS) is a brief, self-administered instrument that not only evaluates depressive symptoms but also both functioning and quality of life.
- Trial name
- CUDOS (NCT01360307)
- Where
- 17 sites in Spain
- Volunteers
- 330 people
- Sponsor
- AstraZeneca
Major Depressive Disorder (MDD)
A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive Disorder
A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial, aim to evaluate the efficacy and safety of dextromethorphan and bupropion sustained-release tablets in Chinese adult patients with major depressive…
- Trial name
- NCT06958692
- Testing
- Dextromethorphan and Bupropion Sustained-Release Tablets
- Where
- China
- Volunteers
- 388 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.